Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2021
Celgene sues Biocon Pharma over drug patents
Celgene Corporation filed a complaint against Biocon Pharma in the District of New Jersey, alleging that Biocon's potential generic drug would infringe Celgene patents. Celgene sought relief including an injunction and a delay to the generic drug's approval effective date; the article reports allegations, not a court determination.
2021
Zydus reaches U.S. patent litigation settlement concerning generic Revlimid
Cadila Healthcare and its subsidiary Zydus Pharmaceuticals (USA), together referred to as Zydus Cadila, announced an agreement with Celgene concerning patents for Revlimid. Under the settlement, the parties will file consent judgments enjoining Zydus Cadila from marketing generic lenalidomide before the patents expire, except as provided in the settlement.
2020
Cipla and Celgene settle Revlimid patent litigation
Cipla announced a settlement of its patent litigation with Celgene concerning Revlimid. The settlement provides for consent judgments enjoining Cipla from marketing generic lenalidomide before the relevant patents expire, subject to settlement terms, and licenses for certain volume-limited US sales after a confidential date following March 2022 and unlimited sales no earlier than January 31, 2026. Cipla’s ability to market the drug is contingent on obtaining ANDA approval.
2020
Dr. Reddy’s and Celgene settle Revlimid patent litigation
Dr. Reddy’s announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy’s to sell volume-limited generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026.
2019
FDA approves Reblozyl for beta thalassemia-related anemia
The U.S. Food and Drug Administration approved Celgene's Reblozyl for anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. The article identifies Acceleron as the drug's co-developer.
2019
Celgene exercises commercial license option for Zymeworks platform candidate
Celgene selected a lead bispecific antibody candidate built using Zymeworks’ Azymetric platform and exercised its option to a commercial license; Zymeworks received a US$7.5 million payment.
2019
Bristol Myers Squibb completes acquisition of Celgene
Bristol Myers Squibb completed its acquisition of Celgene. Celgene became a wholly owned subsidiary of Bristol Myers Squibb.
2015
FDA expands Revlimid's indication for newly diagnosed multiple myeloma
The US Food and Drug Administration expanded the existing indication for Celgene's Revlimid in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.